medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2021, Number 1

<< Back Next >>

VacciMonitor 2021; 30 (1)

Tetanus and diphtheria antitoxin levels related to the HLA-B27 allele in Cuban patients with non-infectious anterior uveitis

Torres-Rives B, Martínez-Téllez G, Matarán-Valdés M, Osorio-Ilas L, Vilches-Lescaille D, Rodríguez-Pelier C, Zúñiga-Rosales Y, Collazo-Mesa T

Language: Spanish
References: 21
Page: 10-17
PDF size: 313.23 Kb.


ABSTRACT

Non-infectious anterior uveitis is an inflammatory disease of the eye that affects the uveal tract and can cause total blindness and other visual disabilities. Autoimmune and inflammatory diseases are associated with qualitative and quantitative alterations in the immune response; therefore, the levels of tetanus and diphtheria antitoxin related to the HLA-B27 allele were evaluated in Cuban patients with non-infectious anterior uveitis. Tetanus and diphtheria antitoxin levels were determined by ELISA in 190 patients with non-infectious anterior uveitis and healthy control individuals. 97.37% of patients with uveitis showed protective tetanus antitoxin levels greater than and equal to 0.1 IU/mL as well as healthy controls (98.95%) (p=0.4385). The proportions of patients with non-infectious anterior uveitis and presumably healthy controls in the different levels of protective tetanus antitoxin were similar (p>0.05) at all levels of protection, as were the geometric mean titers for this antitoxin (p=0.2907). Patients with uveitis aged 65 years or older had a higher proportion of individuals with long-term reliable protective titers (>1.0 IU/mL) of diphtheria antitoxin (p=0.0065). In uveitis patients, no association was observed between the presence of the HLA-B27 allele and the antibody response against tetanus toxoid (p=0.6196) and diphtheria (p=0.1917). Similarly, 37.9% of patients with uveitis and 42% of their controls had non-protective titers (<0.1 IU/mL) of diphtheria antitoxin (0.1148). Most patients with anterior uveitis and control subjects were protected against tetanus (p>0.05), while in patients with uveitis and supposedly healthy controls, aged 18 years or older, the administration of booster doses with diphtheria toxoid should be reevaluated to achieve higher levels of protection against diphtheria.


REFERENCES

  1. Cartaya MB, Barrios MA, Vea HB, Rodriguez KA, Frutos IA, Lescaille DV. Evaluación farmacoterapéutica y evolutiva de uveítis crónicas y recurrentes no infecciosas. Rev Cubana Oftalmol. 2014;27(3):369-89. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762014000300006.

  2. Wakefield D, Yates W, Amjadi Sh, McCluskey P. HLA-B27 Anterior Uveitis: Inmunology and Inmunopathology. Ocul Immunol Inflamm. 2016;24(4):450-9. doi: https://10.3109/09273948.2016.1158283.

  3. Fischer A, Provot J, Jais JP, Alcais A, Mahlaoui N, members of the CEREDIH French PID study group. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2017;140(5):1388-93.e8. doi: https://10.1016/j.jaci.2016.12.978.

  4. Rondaan C, Furer V, Heijstek MW, Agmon-Levin N, Bijl M, Breedveld FC, et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendatios. RMD Open. 2019;5:e001035. doi: https://10.1136/ rmdopen-2019-001035.

  5. Ochoa R, Martínez JC, Ferriol X, Sotolongo F. Niveles de antitoxina tetánica y diftérica en recién nacidos y niños preescolares cubanos. Rev Cubana Med Trop 2006;58(1):44-9. Disponible en: http://www.bvs.sld.cu/revistas/mtr/vol58_1_06/mtr08106.pdf.

  6. Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: A review. Vaccine. 2018;36(36):5350-57. doi: https://10.1016/j.vaccine.2017.07.062.

  7. López-Ambrón L, Egües-Torres LI, Pérez-Carreras A, Galindo-Santana BM, Galindo-Sardiña MA, Resik-Aguirre S, et al. Experiencia cubana en inmunización, 1962-2016. Rev Panam Salud Publica. 2018;42:e34. doi: https://10.26633/RPSP.2018.34.

  8. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-4. doi: https://10.1001/jama.2013.281053

  9. Rodríguez-Pelier CV, Zúñiga-Rosales Y, Torres-Rives B, Matarán-Valdéz M. Validación de un ensayo inmunoenzimático tipo ELISA para cuantificar niveles de antitoxina diftérica en suero humano. Rev haban cienc méd. 2018;17(4):527-39. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/2113.

  10. Rodríguez-Pelier CV, Martínez-Téllez G, Torres-Rives B, Zúñiga-Rosales Y, Alles-Gustavo A, Martínez-Perera A. Estandarización y validación de un ELISA para la cuantificación de antitoxina tetánica en suero humano. Rev haban cienc méd. 2013;12(4)534-41. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2013000400005&lng=es.

  11. Miller SA, Dykes DD, Polesky Hf. A simple salting out procedure for extracting DNA from human nucleotide cells. Nucleic Acids Res. 1988;16:1215-8. doi: https://10.1093/nar/16.3.1215.

  12. Bon M, Dybicz A, Bergh F. Genotyping of HLA-B27 by Real-Time PCR without Hybridization Probes. Clin Chem. 2000;46(7):1000-2. doi: https://10.1093/nar/16.3.1215.

  13. World Health Organization. The immunological basis for immunization series: module 3: tetanus. Geneva: WHO; 2018. Disponible en: https://www.who.int/publications-detail/the-immunological-basis-for-immunization-series-module-3-tetanus-update-2018 .

  14. Fernández R, Ochoa R, Agüero B. Evaluación de la inmunidad contra el tétanos y la difteria en trabajadores del Instituto Finlay ocupacionalmente expuestos a riesgos. VacciMonitor. 2004;10(3):10-7. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2004000300002&lng=es .

  15. Csuka D, Czirjak L, Hobor R, Illes Z, Banati M, Rajczy K, et al. Effective humoral immunity against diphtheria and tetanus in patients with systemic lupus erythematosus or myasthenia gravis. Mol Immunol. 2013;54:453-6. doi: https://10.1016/j.molimm.2013.01.012.

  16. Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. J Cutan Med Surg. 2019;23(1):50-74. doi: https://10.1177/1203475418811335.

  17. Petráš M, Oleár V, Molitorisová M, Dáňová J, Čelko AM, Nováková E, et al. Factors Influencing Persistence of Diphtheria Immunity and Immune Response to a Booster Dose in Healthy Slovak Adults. Vaccines (Basel). 2019;7(4):139-48. doi: https://10.3390/vaccines7040139.

  18. Weinberger B. Adult vaccination against tetanus and diphtheria: the European perspective. Clin Exp Immunol. 2017;187(1):93-9. doi: https://10.1111/cei.12822.

  19. World Health Organization. Diphtheria vaccine. Review of evidence on vaccine effectiveness and immunogenicity to assess the duration of protection ≥10 years after the last booster dose. Geneva: WHO ; 2017. Disponible en: https://www.who.int/immunization/sage/meetings/2017/april/2_Review_Diphtheria_results_April2017_final_clean.pdf.

  20. van Tok MN, Satumtira N, Dorris M, Pots D, Slobodin G, van de Sande MG, et al. Innate Immune Activation Can Trigger Experimental Spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats. Front Immunol. 2017;8:920-32. doi: https://10.3389/fimmu.2017.00920.

  21. Ovsyannikova IG, Pankratz VS, Larrabee BR, Jacobson RM, Poland GA. HLA genotypes and rubella vaccine immune response: additional evidence. Vaccine. 2014;32(33):4206-13. doi: https://10.1016/j.vaccine.2014.04.091.




2020     |     www.medigraphic.com